Literature DB >> 21062272

Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders.

A Kloska1, J Jakóbkiewicz-Banecka, A Tylki-Szymańska, B Czartoryska, G Węgrzyn.   

Abstract

Familial X-chromosome inactivation (XCI) skewing was investigated in a family in which a female mucopolysaccharidosis type II (MPS II) (Hunter syndrome, an X-linked genetic disease) occurred. Among eight related females aged under 60 years from three generations who were tested, four revealed a non-random pattern of XCI. Detailed genetic analysis failed to find mutations in genes that were previously reported as important for the XCI process. Haplotype analysis excluded linkage of non-random XCI with genes localized on the X-chromosome. We propose that analysis of the XCI pattern should be taken into consideration when assessing risk factors for X-linked recessive genetic disorders.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062272     DOI: 10.1111/j.1399-0004.2010.01574.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  10 in total

1.  De novo MECP2 duplications in two females with intellectual disability and unfavorable complete skewed X-inactivation.

Authors:  Nathalie Fieremans; Marijke Bauters; Stefanie Belet; Jelle Verbeeck; Anna C Jansen; Sara Seneca; Filip Roelens; Elfride De Baere; Peter Marynen; Guy Froyen
Journal:  Hum Genet       Date:  2014-07-19       Impact factor: 4.132

2.  Identification of Intellectual Disability Genes in Female Patients with a Skewed X-Inactivation Pattern.

Authors:  Nathalie Fieremans; Hilde Van Esch; Maureen Holvoet; Gert Van Goethem; Koenraad Devriendt; Monica Rosello; Sonia Mayo; Francisco Martinez; Shalini Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski; Joris R Vermeesch; Peter Marynen; Guy Froyen
Journal:  Hum Mutat       Date:  2016-05-25       Impact factor: 4.878

Review 3.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

4.  Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study.

Authors:  Encarna Guillén-Navarro; María Rosario Domingo-Jiménez; Carlos Alcalde-Martín; Ramón Cancho-Candela; María Luz Couce; Enrique Galán-Gómez; Olga Alonso-Luengo
Journal:  Orphanet J Rare Dis       Date:  2013-06-25       Impact factor: 4.123

5.  Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G>A (p.Gln293Gln) synonymous variation in a female create exonic splicing.

Authors:  Huiwen Zhang; Jing Li; Xinshun Zhang; Yu Wang; Wenjuan Qiu; Jun Ye; Lianshu Han; Xiaolan Gao; Xuefan Gu
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

6.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

7.  Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis Type II.

Authors:  Zackary M Herbst; Leslie Urdaneta; Terri Klein; Barbara K Burton; Khaja Basheeruddin; Hsuan-Chieh Liao; Maria Fuller; Michael H Gelb
Journal:  Int J Neonatal Screen       Date:  2022-01-21

Review 8.  Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.

Authors:  Paweł Zapolnik; Antoni Pyrkosz
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

9.  Detailed pedigree analyses and prenatal diagnosis for a family with mucopolysaccharidosis type II.

Authors:  Chuan Zhang; Shengju Hao; ZhaoYan Meng; Ling Hui; Yan Wang; Feng Xuan; Xue Chen; Xing Wang; Furong Zheng; Lei Zheng; Bingbo Zhou; Xinqi Wu; Qinghua Zhang; Zongfu Cao
Journal:  BMC Med Genomics       Date:  2021-06-30       Impact factor: 3.063

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.